Vistagen Therapeutics (VTGN) Operating Leases (2019 - 2025)
Vistagen Therapeutics (VTGN) has disclosed Operating Leases for 7 consecutive years, with $431000.0 as the latest value for Q4 2025.
- Quarterly Operating Leases fell 61.17% to $431000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $431000.0 through Dec 2025, down 61.17% year-over-year, with the annual reading at $948000.0 for FY2025, 39.62% down from the prior year.
- Operating Leases hit $431000.0 in Q4 2025 for Vistagen Therapeutics, down from $610000.0 in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $3.6 million in Q2 2021 to a low of $431000.0 in Q4 2025.
- Historically, Operating Leases has averaged $1.9 million across 5 years, with a median of $1.9 million in 2023.
- Biggest five-year swings in Operating Leases: decreased 8.23% in 2021 and later crashed 61.17% in 2025.
- Year by year, Operating Leases stood at $2.7 million in 2021, then decreased by 17.31% to $2.2 million in 2022, then dropped by 23.74% to $1.7 million in 2023, then plummeted by 35.21% to $1.1 million in 2024, then plummeted by 61.17% to $431000.0 in 2025.
- Business Quant data shows Operating Leases for VTGN at $431000.0 in Q4 2025, $610000.0 in Q3 2025, and $783000.0 in Q2 2025.